China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999

Watchlist Manager
China Resources Sanjiu Medical & Pharmaceutical Co Ltd Logo
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
Watchlist
Price: 46.55 CNY 0.67% Market Closed
Market Cap: 59.8B CNY
Have any thoughts about
China Resources Sanjiu Medical & Pharmaceutical Co Ltd?
Write Note
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
/
Income Statement
/
Research & Development

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SZSE:000999
Research & Development
-¥768.2m
CAGR 3-Years
0%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-¥2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-¥197m
CAGR 3-Years
-24%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-¥5.8B
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-¥333.6m
CAGR 3-Years
-10%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Research & Development
-¥712.5m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China Resources Sanjiu Medical & Pharmaceutical Co Ltd
Glance View

Market Cap
59.8B CNY
Industry
Pharmaceuticals

In the intricate landscape of China's healthcare sector, China Resources Sanjiu Medical & Pharmaceutical Co Ltd stands as a significant player, weaving its extensive roots in both traditional and modern medicine. Emerging from the fusion of innovation and heritage, the company operates under the wing of China Resources, a state-owned conglomerate. This affiliation affords it a robust platform to traverse the dual path of pharmaceutical manufacturing and healthcare services. The company primarily engages in the development, production, and sale of a diverse range of pharmaceutical products, from essential medicines to over-the-counter dietary supplements. These offerings include both Western-style pharmaceuticals and traditional Chinese medicines, such as its widely recognized "999" branded cold medicines, allowing the company to leverage its expertise in a market with growing demand for holistic health solutions. China Resources Sanjiu generates its revenue through multiple channels, capitalizing on both domestic and international market opportunities. By integrating research and development with an efficient distribution network, the company ensures that its products reach a broad consumer base. In recent years, the company has focused on enhancing its research capabilities, investing heavily in developing innovative drugs that address prevalent health challenges. Sales of their proprietary and branded products are supported by strategic marketing initiatives, which highlight Sanjiu's commitment to quality and efficacy. Furthermore, the company's synergy with its parent organization facilitates expansions and strategic partnerships, reinforcing its competitive advantage in an industry marked by rapid evolution and stringent regulatory landscapes. With a foothold in both retail and institutional markets, China Resources Sanjiu Medical & Pharmaceutical Co Ltd continues to play a pivotal role in enhancing access to healthcare across China and beyond.

Intrinsic Value
58.69 CNY
Undervaluation 21%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Research & Development?
Research & Development
-768.2m CNY

Based on the financial report for Sep 30, 2024, China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Research & Development amounts to -768.2m CNY.

What is China Resources Sanjiu Medical & Pharmaceutical Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-14%

Over the last year, the Research & Development growth was -10%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.